188 related articles for article (PubMed ID: 38030318)
41. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
42. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
43. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.
Hill A; Rother RP; Wang X; Morris SM; Quinn-Senger K; Kelly R; Richards SJ; Bessler M; Bell L; Hillmen P; Gladwin MT
Br J Haematol; 2010 May; 149(3):414-25. PubMed ID: 20230403
[TBL] [Abstract][Full Text] [Related]
44. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
[TBL] [Abstract][Full Text] [Related]
45. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
46. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
Risitano AM; Kulasekararaj AG; Lee JW; Maciejewski JP; Notaro R; Brodsky R; Huang M; Geffner M; Browett P
Haematologica; 2021 Dec; 106(12):3188-3197. PubMed ID: 33121236
[TBL] [Abstract][Full Text] [Related]
47. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
Peixoto VP; Prudêncio C; Vieira M
Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
[TBL] [Abstract][Full Text] [Related]
48. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
[TBL] [Abstract][Full Text] [Related]
49. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
50. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
51. Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test.
Höchsmann B; Leichtle R; von Zabern I; Kaiser S; Flegel WA; Schrezenmeier H
Vox Sang; 2012 Feb; 102(2):159-66. PubMed ID: 21929681
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
Misawa S; Kuwabara S; Sato Y; Yamaguchi N; Nagashima K; Katayama K; Sekiguchi Y; Iwai Y; Amino H; Suichi T; Yokota T; Nishida Y; Kanouchi T; Kohara N; Kawamoto M; Ishii J; Kuwahara M; Suzuki H; Hirata K; Kokubun N; Masuda R; Kaneko J; Yabe I; Sasaki H; Kaida KI; Takazaki H; Suzuki N; Suzuki S; Nodera H; Matsui N; Tsuji S; Koike H; Yamasaki R; Kusunoki S;
Lancet Neurol; 2018 Jun; 17(6):519-529. PubMed ID: 29685815
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.
Quist SW; Postma AJ; Myrén KJ; de Jong LA; Postma MJ
Eur J Health Econ; 2023 Dec; 24(9):1455-1472. PubMed ID: 36633725
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC; Cheriyan J; Cope AP; Galloway J; Wilkinson I; Bond S; Norton S; Banham-Hall E; Bayes H; Kostapanos M; Nodale M; Petchey WG; Sheeran T; Underwood J; Jayne DR;
Lancet Respir Med; 2023 Dec; 11(12):1064-1074. PubMed ID: 37977159
[TBL] [Abstract][Full Text] [Related]
56. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria.
Yoo JJ; Chonat S
Expert Rev Hematol; 2022 May; 15(5):385-392. PubMed ID: 35502699
[TBL] [Abstract][Full Text] [Related]
57. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
58. [Perioperative management of laparoscopic cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab treatment].
Kimura M; Nishiyama Y; Ueda H; Kitajo A; Arimatsu T; Kuboki M; Takahata A; Saito M; Sakashita C; Okada K; Umezawa Y; Nagao T; Yamamoto M; Tohda S; Tanabe M; Mori T; Nogami A
Rinsho Ketsueki; 2022; 63(4):260-264. PubMed ID: 35491214
[TBL] [Abstract][Full Text] [Related]
59. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
[TBL] [Abstract][Full Text] [Related]
60. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.
McKeage K
Drugs; 2011 Dec; 71(17):2327-45. PubMed ID: 22085388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
